25 results on '"Alvarez-Rivas N"'
Number of results to display per page
Search Results
2. POS0804 TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY
- Author
-
Prieto-Peña, D., primary, Loricera, J., additional, Castañeda, S., additional, Moriano, C., additional, Bernabéu, P., additional, Vela-Casasempere, P., additional, Narváez, J., additional, Aldasoro, V., additional, Maíz, O., additional, Fernández-López, C., additional, Freire González, M., additional, Melero, R., additional, Villa-Blanco, I., additional, González-Alvarez, B., additional, Solans-Laqué, R., additional, Callejas-Rubio, J. L., additional, Fernández-Díaz, C., additional, Rubio Romero, E., additional, García Morillo, S., additional, Minguez, M., additional, Fernández-Carballido, C., additional, De Miguel, E., additional, Sanchez-Martin, J., additional, Fernández, E., additional, Melchor, S., additional, Salgado-Pérez, E., additional, Bravo, B., additional, Romero-Yuste, S., additional, Galíndez-Agirregoikoa, E., additional, Sivera, F., additional, Ferraz-Amaro, I., additional, Hidalgo, C., additional, Romero-Gómez, C., additional, Galisteo, C., additional, Moya, P., additional, Alvarez-Rivas, N., additional, Mendizabal, J., additional, Nieto González, J. C., additional, De Dios, J. R., additional, Andreu, J. L., additional, Pérez de Pedro, I., additional, Revenga, M., additional, Alonso Valdivieso, J. L., additional, Rosa, R. M., additional, De la Morena, I., additional, Fernández-Llanio, N., additional, Labrador, E., additional, Roman-Ivorra, J. A., additional, Ortiz-Sanjuán, F., additional, García-Valle, A., additional, Gallego, A., additional, Iñiguez, C., additional, Garrido-Puñal, N., additional, De la Torre, R., additional, López-González, R., additional, Collado, P., additional, Raya, E., additional, Navarro, F., additional, Mas, A. J., additional, Ordás, C., additional, Boquet, M. D., additional, Velloso Feijoo, M. L., additional, Campos Fernández, C., additional, Rúa-Figueroa, I., additional, Conesa, A., additional, Manrique Arija, S., additional, González-Gay, M. A., additional, and Blanco, R., additional
- Published
- 2022
- Full Text
- View/download PDF
3. TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY
- Author
-
Prieto-Pena D, Loricera J, Castaneda S, Moriano C, Bernabeu P, Vela-Casasempere P, Narvaez J, Aldasoro V, Maiz O, Fernandez-Lopez C, Gonzalez M, Melero R, Villa-Blanco I, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Sanchez-Martin J, Fernandez E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Galindez-Agirregoikoa E, Sivera F, Ferraz-Amaro I, Hidalgo C, Romero-Gomez C, Galisteo C, Moya P, Alvarez-Rivas N, Mendizabal J, Gonzalez J, De Dios J, Andreu J, de Pedro I, Revenga M, Valdivieso J, Rosa R, De la Morena I, Fernandez-Llanio N, Labrador E, Roman-Ivorra J, Ortiz-Sanjuan F, Garcia-Valle A, Gallego A, Iniguez C, Garrido-Punal N, De la Torre R, Lopez-Gonzalez R, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Feijoo M, Fernandez C, Rua-Figueroa I, Conesa A, Arija S, Gonzalez-Gay M, and Blanco R
- Published
- 2022
4. Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases
- Author
-
Sanchez-Bilbao L, Loricera J, Castaneda S, Moriano C, Narvaez J, Aldasoro V, Maiz O, Melero R, Villa J, Vela P, Romero-Yuste S, Callejas J, De Miguel E, Galindez-Agirregoikoa E, Sivera F, Fernandez-Lopez J, Galisteo C, Ferraz-Amaro I, Nieto J, de Dios J, Sanchez J, Fernandez E, de la Morena I, Moya P, Solans-Laque R, Andreu J, Revenga M, Labrador E, Garcia-Valle A, Gallego A, Iniguez C, Hidalgo C, Garrido-Punal N, Lopez-Gonzalez R, Roman-Ivorra J, Arija S, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Alvarez-Rivas N, Velloso-Feijoo M, Campos-Fernandez C, Rua-Figueroa I, Conesa A, Salgado E, Gonzalez-Gay M, and Blanco R
- Published
- 2021
5. Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
- Author
-
Sanchez-Bilbao L, Loricera J, Acha J, Moriano C, Narvaez J, Aldasoro V, Maiz O, Melero R, Villa J, Vela P, Romero-Yuste S, Callejas J, De Miguel E, Galindez-Agirregoikoa E, Sivera F, Fernandez-Lopez J, Galisteo C, Ferraz-Amaro I, Nieto J, de Dios J, Sanchez J, Fernandez E, de la Morena I, Moya P, Solans-Laque R, Andreu J, Revenga M, Pinillos V, Garcia-Valle A, Gallego A, Iniguez C, Hidalgo C, Garrido-Punal N, Lopez-Gonzalez R, Roman-Ivorra J, Arija S, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Alvarez-Rivas N, Velloso-Feijoo M, Campos-Fernandez C, Rua-Figueroa I, Conesa A, Salgado E, Gonzalez-Gay M, and Blanco R
- Published
- 2021
6. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients
- Author
-
Calderon-Goercke M, Castaneda S, Aldasoro V, Villa I, Moriano C, Romero-Yuste S, Narvaez J, Gomez-Arango C, Perez-Pampin E, Melero R, Becerra-Fernandez E, Revenga M, Alvarez-Rivas N, Galisteo C, Sivera F, De Miguel E, Prieto-Pena D, Gonzalez-Gay M, Hernandez J, Blanco R, and Tocilizumab Giant Cell Arteritis S
- Subjects
Immunosuppressive drugs ,Tocilizumab ,Cranial arteritis ,Monotherapy ,Giant cell arteritis - Abstract
Objective: To compare the efficacy and safety of TCZ in monotherapy (TCZ(MONO)) vs. combined with conventional immunosuppressive drugs (TCZ(COMBO)) in Giant Cell Arteritis (GCA) in a clinical practice scenario. Methods: Multicenter study of 134 patients with refractory GCA. Patients on TCZ(MONO) (n = 82) were compared with those on TCZ(COMBO) (n = 52). Drugs were methotrexate (MTX) (n = 48), azathioprine (n = 3), and lefluno-mide (n = 1). The main outcomes were: prolonged remission (normalization of clinical and laboratory parameters for at least 6 months) and the number of relapses. Results: Patients on TCZ(COMBO) were younger (68.8 +/- 8.0 vs 71.2 +/- 9.0 years; p = 0.04), with a trend to a longer GCA duration (median [IQR],18.5 [6.25-34.0] vs. 13.0 [7.75-33.5] months; p = 0.333), higher C-reactive protein (CRP) levels (2.1[1-4.7] vs 1.2 [0.2-2.4] mg/dL; p = 0.003), and more prevalence of extra-cranial large vessel vasculitis (LVV) (57% vs. 34.1%; p = 0.007). In both groups, rapid and sustained improvement was observed. Despite the longer GCA duration, and the higher CRP levels and prevalence of LVV in the TCZ(COMBO), the improvement was similar in both groups at 12 months. Moreover, in the TCZ(COMBO) group, prolonged remission was significantly higher at 12-month. Relapses and serious adverse events were similar in both groups. Conclusion: In clinical practice, TCZ in monotherapy or combined with conventional immunosuppressive agents is effective and safe in patients with GCA. Nevertheless, the addition of immunosuppressive drugs, usually MTX, seems to allow a higher rate of prolonged remission, even in patients with a longer GCA duration, more extra-cranial LVV involvement, and higher acute-phase reactants. (C) 2021 Elsevier Inc. All rights reserved.
- Published
- 2021
7. Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review
- Author
-
Prieto-Pena D, Bernabeu P, Vela P, Narvaez J, Fernandez-Lopez J, Freire-Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Rubio J, Ortego N, Fernandez-Diaz C, Rubio E, Garcia-Morillo S, Minguez M, Fernandez-Carballido C, de Miguel E, Melchor S, Salgado E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Ortiz-Sanjuan F, de Pedro I, Alonso-Valdivielso J, Perez-Sanchez L, Roldan R, Fernandez-Llanio N, de la Torre R, Suarez S, Cabrera M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R
- Subjects
Takayasu's arteritis ,cDMARDs ,biological therapy ,Caucasian ,Tocilizumab - Abstract
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.
- Published
- 2021
8. TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS
- Author
-
Prieto-Pena D, Bernabeu P, Vela-Casasempere P, Narvaez J, Fernandez-Lopez C, Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Ortego N, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Arija S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Sanjuan F, de Pedro I, Valdivieso J, Laura P, Rosa R, Fernandez-Llanio N, de la Torre R, Suarez S, Montesa M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R
- Published
- 2021
9. OP0064 TOCILIZUMAB IN CRANIAL AND EXTRACRANIAL REFRACTORY GIANT CELL ARTERITIS: A MULTICENTER STUDY OF 312 CASES
- Author
-
Sanchez-Bilbao, L., primary, Loricera, J., additional, Aldasoro, V., additional, Valdivieso-Achá, J. P., additional, Villa-Blanco, I., additional, Maiz, O., additional, Melero, R., additional, Moriano, C., additional, Sánchez, J., additional, De Miguel, E., additional, Perez-Pampín, E., additional, De Dios, J. R., additional, Nieto González, J. C., additional, Galíndez-Agirregoikoa, E., additional, Moya, P., additional, Sivera, F., additional, Andréu Sánchez, J. L., additional, Pinillos, V., additional, García-Valle, A., additional, Vela-Casasempere, P., additional, Alvarez-Rivas, N., additional, Revenga, M., additional, Manrique Arija, S., additional, Fernández-López, C., additional, Raya, E., additional, Hidalgo, C., additional, López-González, R., additional, Campos Fernández, C., additional, Juan-Mas, A., additional, Arca, B., additional, Rua-Figueroa, I., additional, Boquet, M. D., additional, García, A., additional, Gallego, A., additional, Salgado-Pérez, E., additional, González-Gay, M. A., additional, and Blanco, R., additional
- Published
- 2021
- Full Text
- View/download PDF
10. AB0366 TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS
- Author
-
Prieto-Peña, D., primary, Bernabéu, P., additional, Vela-Casasempere, P., additional, Narváez, J., additional, Fernández-López, C., additional, Freire González, M., additional, González-Alvarez, B., additional, Solans-Laqué, R., additional, Callejas-Rubio, J. L., additional, Ortego, N., additional, Fernández-Díaz, C., additional, Rubio Romero, E., additional, García Morillo, S., additional, Minguez, M., additional, Fernández-Carballido, C., additional, De Miguel, E., additional, Melchor, S., additional, Salgado-Pérez, E., additional, Bravo, B., additional, Romero-Yuste, S., additional, Salvatierra, J., additional, Hidalgo, C., additional, Manrique Arija, S., additional, Romero-Gómez, C., additional, Moya, P., additional, Alvarez-Rivas, N., additional, Mendizabal, J., additional, Ortiz Sanjuan, F. M., additional, Pérez de Pedro, I., additional, Alonso Valdivieso, J. L., additional, Laura, P. S., additional, Rosa, R. M., additional, Fernández-Llanio, N., additional, Gómez de la Torre, R., additional, Suarez, S., additional, Montesa, M. J., additional, Delgado Sanchez, M., additional, Loricera, J., additional, Atienza-Mateo, B., additional, Castañeda, S., additional, González-Gay, M. A., additional, and Blanco, R., additional
- Published
- 2021
- Full Text
- View/download PDF
11. SAT0075 ABATACEPT IN COMBINATION WITH METOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS ASSOCIATED TO INTERSTITIAL LUNG DISEASE: NATIONAL MULTICENTER STUDY OF 263 PATIENTS
- Author
-
Fernández-Díaz, C., primary, Castañeda, S., additional, Melero, R., additional, Loricera, J., additional, Ortiz-Sanjuán, F., additional, Juan-Mas, A., additional, Carrasco-Cubero, C., additional, Rodriguéz-Muguruza, S., additional, Rodrigez-Garcia, S., additional, Castellanos-Moreira, R., additional, Almodovar, R., additional, Aguilera Cros, C., additional, Villa-Blanco, I., additional, Ordoñez, S., additional, Romero-Yuste, S., additional, Ojeda-Garcia, C., additional, Moreno, M., additional, Bonilla, G., additional, Hernández-Rodriguez, I., additional, Lopez Corbeto, M., additional, Andréu Sánchez, J. L., additional, Pérez Sandoval, T., additional, López Robles, A., additional, Carreira, P., additional, Mena-Vázquez, N., additional, Peralta-Ginés, C., additional, Urruticoechea-Arana, A., additional, Arboleya Rodríguez, L. M., additional, Narváez, J., additional, Palma Sanchez, D., additional, Maiz-Alonso, O., additional, Fernández-Leroy, J., additional, Cabezas-Rodriguez, I., additional, Castellví, I., additional, Ruibal-Escribano, A., additional, De Dios-Jiménez Aberásturi, J., additional, Vela-Casasempere, P., additional, González-Montagut Gómez, C., additional, Blanco, J. M., additional, Alvarez-Rivas, N., additional, Del-Val, N., additional, Rodíguez-Gómez, M., additional, Salgado-Pérez, E., additional, Fernández-López, C., additional, Cervantes Pérez, E. C., additional, Devicente-Delmas, A., additional, Garcia-Magallon, B., additional, Hidalgo, C., additional, Fernández, S., additional, García-Fernández, E., additional, López-Sánchez, R., additional, Castro, S., additional, Morales-Garrido, P., additional, García-Valle, A., additional, Expósito, R., additional, Exposito-Perez, L., additional, Pérez Albaladejo, L., additional, García-Aparicio, Á., additional, Blanco, R., additional, and González-Gay, M. A., additional
- Published
- 2020
- Full Text
- View/download PDF
12. OP0033 OPTIMIZATION OF TOCILIZUMAB THERAPY IN GIANT CELL ARTERITIS. A MULTICENTER REAL-LIFE STUDY OF 134 PATIENTS
- Author
-
Calderón-Goercke, M., primary, Prieto-Peña, D., additional, Castañeda, S., additional, Moriano, C., additional, Becerra-Fernández, E., additional, Revenga, M., additional, Alvarez-Rivas, N., additional, Galisteo, C., additional, Prior-Español, Á., additional, Galindez, E., additional, Hidalgo, C., additional, Manrique Arija, S., additional, De Miguel, E., additional, Salgado-Pérez, E., additional, Aldasoro, V., additional, Villa-Blanco, I., additional, Romero-Yuste, S., additional, Narváez, J., additional, Gomez-Arango, C., additional, Perez-Pampín, E., additional, Melero, R., additional, Sivera, F., additional, Olive, A., additional, Álvarez del Buergo, M., additional, Marena Rojas, L., additional, Fernández-López, C., additional, Navarro, F., additional, Raya, E., additional, Arca, B., additional, Solans-Laqué, R., additional, Conesa, A., additional, Vázquez, C., additional, Román-Ivorra, J. A., additional, Lluch, P., additional, Vela-Casasempere, P., additional, Torres-Martín, C., additional, Nieto, J. C., additional, Ordas-Calvo, C., additional, Luna-Gomez, C., additional, Toyos Sáenz de Miera, F. J., additional, Fernández-Llanio, N., additional, García, A., additional, Hernández, J. L., additional, González-Gay, M. A., additional, and Blanco, R., additional
- Published
- 2020
- Full Text
- View/download PDF
13. THU0297 SERIOUS INFECTIONS IN 134 PATIENTS WITH GIANT CELL ARTERITIS WITH TOCILIZUMAB IN CLINICAL PRACTICE. FREQUENCY, TYPE AND CLINICAL ASSOCIATIONS
- Author
-
Calderón-Goercke, M., primary, Prieto-Peña, D., additional, Castañeda, S., additional, Moriano, C., additional, Becerra-Fernández, E., additional, Revenga, M., additional, Alvarez-Rivas, N., additional, Galisteo, C., additional, Prior-Español, Á., additional, Galindez, E., additional, Hidalgo, C., additional, Manrique Arija, S., additional, De Miguel, E., additional, Salgado-Pérez, E., additional, Aldasoro, V., additional, Villa-Blanco, I., additional, Romero-Yuste, S., additional, Narváez, J., additional, Gomez-Arango, C., additional, Perez-Pampín, E., additional, Melero, R., additional, Sivera, F., additional, Fernández-Díaz, C., additional, Olive, A., additional, Álvarez del Buergo, M., additional, Marena Rojas, L., additional, Fernández-López, C., additional, Navarro, F., additional, Raya, E., additional, Arca, B., additional, Solans-Laqué, R., additional, Conesa, A., additional, Vázquez, C., additional, Román-Ivorra, J. A., additional, Lluch, P., additional, Vela-Casasempere, P., additional, Torres-Martín, C., additional, Nieto, J. C., additional, Ordas-Calvo, C., additional, Luna-Gomez, C., additional, Toyos Sáenz de Miera, F. J., additional, Fernández-Llanio, N., additional, García, A., additional, González-Vela, C., additional, García-Fernández, J., additional, Vicente-Gómez, P., additional, García-Manzanares, Á., additional, Ortego, N., additional, Ortiz-Sanjuán, F., additional, Corteguera, M., additional, Hernández, J. L., additional, González-Gay, M. A., additional, and Blanco, R., additional
- Published
- 2020
- Full Text
- View/download PDF
14. SAT0035 RESPONSE TO ABATACEPT OF DIFFERENT PATTERNS OF INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: NATIONAL MULTICENTER STUDY OF 263 PATIENTS
- Author
-
Fernández-Díaz, C., primary, Castañeda, S., additional, Melero, R., additional, Loricera, J., additional, Ortiz-Sanjuán, F., additional, Juan-Mas, A., additional, Carrasco-Cubero, C., additional, Rodriguéz-Muguruza, S., additional, Rodrigez-Garcia, S., additional, Castellanos-Moreira, R., additional, Almodovar, R., additional, Aguilera Cros, C., additional, Villa-Blanco, I., additional, Ordoñez, S., additional, Romero-Yuste, S., additional, Ojeda-Garcia, C., additional, Moreno, M., additional, Bonilla, G., additional, Hernández-Rodriguez, I., additional, Lopez Corbeto, M., additional, Andréu Sánchez, J. L., additional, Pérez Sandoval, T., additional, López Robles, A., additional, Carreira, P., additional, Mena-Vázquez, N., additional, Peralta-Ginés, C., additional, Urruticoechea-Arana, A., additional, Arboleya Rodríguez, L. M., additional, Narváez, J., additional, Palma Sanchez, D., additional, Maiz-Alonso, O., additional, Fernández-Leroy, J., additional, Cabezas-Rodriguez, I., additional, Castellví, I., additional, Ruibal-Escribano, A., additional, De Dios-Jiménez Aberásturi, J., additional, Vela-Casasempere, P., additional, González-Montagut Gómez, C., additional, Blanco, J. M., additional, Alvarez-Rivas, N., additional, Del-Val, N., additional, Rodíguez-Gómez, M., additional, Salgado-Pérez, E., additional, Fernández-López, C., additional, Cervantes Pérez, E. C., additional, Devicente-Delmas, A., additional, Garcia-Magallon, B., additional, Hidalgo, C., additional, Fernández, S., additional, López-Sánchez, R., additional, García-Fernández, E., additional, Castro, S., additional, Morales-Garrido, P., additional, García-Valle, A., additional, Expósito, R., additional, Exposito-Perez, L., additional, Pérez Albaladejo, L., additional, García-Aparicio, Á., additional, González-Gay, M. A., additional, and Blanco, R., additional
- Published
- 2020
- Full Text
- View/download PDF
15. SAT0270 TOCILIZUMAB IN REFRACTORY TAKAYASU ARTERITIS. OPEN-LABEL NATIONAL MULTICENTER STUDY OF 53 PATIENTS OF CLINICAL PRACTICE
- Author
-
Prieto-Peña, D., primary, Calderón-Goercke, M., additional, Bernabéu, P., additional, Vela-Casasempere, P., additional, Narváez, J., additional, Fernández-López, C., additional, Freire González, M., additional, González-Alvarez, B., additional, Solans-Laqué, R., additional, Callejas-Rubio, J. L., additional, Ortego, N., additional, Fernández-Díaz, C., additional, Rubio Romero, E., additional, García Morillo, S., additional, Minguez, M., additional, Fernández-Carballido, C., additional, De Miguel, E., additional, Melchor, S., additional, Salgado-Pérez, E., additional, Bravo, B., additional, Romero-Yuste, S., additional, Salvatierra, J., additional, Hidalgo, C., additional, Manrique Arija, S., additional, Romero-Gómez, C., additional, Moya, P., additional, Alvarez-Rivas, N., additional, Mendizabal, J., additional, Ortiz Sanjuan, F. M., additional, Pérez de Pedro, I., additional, Loricera, J., additional, Castañeda, S., additional, González-Gay, M. A., additional, and Blanco, R., additional
- Published
- 2020
- Full Text
- View/download PDF
16. OP0212 ABATACEPT IN INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 263 PATIENTS
- Author
-
Fernández-Díaz, C., primary, Castañeda, S., additional, Melero, R., additional, Loricera, J., additional, Ortiz-Sanjuán, F., additional, Juan-Mas, A., additional, Carrasco-Cubero, C., additional, Rodriguéz-Muguruza, S., additional, Rodrigez-Garcia, S., additional, Castellanos-Moreira, R., additional, Almodovar, R., additional, Aguilera Cros, C., additional, Villa-Blanco, I., additional, Ordoñez, S., additional, Romero-Yuste, S., additional, Ojeda-Garcia, C., additional, Moreno, M., additional, Bonilla, G., additional, Hernández-Rodriguez, I., additional, Lopez Corbeto, M., additional, Andréu Sánchez, J. L., additional, Pérez Sandoval, T., additional, López Robles, A., additional, Carreira, P., additional, Mena-Vázquez, N., additional, Peralta-Ginés, C., additional, Urruticoechea-Arana, A., additional, Arboleya Rodríguez, L. M., additional, Narváez, J., additional, Palma Sanchez, D., additional, Maiz-Alonso, O., additional, Fernández-Leroy, J., additional, Cabezas-Rodriguez, I., additional, Castellví, I., additional, Ruibal-Escribano, A., additional, De Dios-Jiménez Aberásturi, J., additional, Vela-Casasempere, P., additional, González-Montagut Gómez, C., additional, Blanco, J. M., additional, Alvarez-Rivas, N., additional, Del-Val, N., additional, Rodíguez-Gómez, M., additional, Salgado-Pérez, E., additional, Fernández-López, C., additional, Cervantes Pérez, E. C., additional, Devicente-Delmas, A., additional, Garcia-Magallon, B., additional, Hidalgo, C., additional, Fernández, S., additional, García-Fernández, E., additional, López-Sánchez, R., additional, Castro, S., additional, Morales-Garrido, P., additional, García-Valle, A., additional, Expósito, R., additional, Exposito-Perez, L., additional, Pérez Albaladejo, L., additional, García-Aparicio, Á., additional, González-Gay, M. A., additional, and Blanco, R., additional
- Published
- 2020
- Full Text
- View/download PDF
17. Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients
- Author
-
Fernandez-Diaz, C, Melero, R, Loricera, J, Castaneda, S, Ortiz-Sanjuan, F, Casafont-Sole, I, Carrasco-Cubero, C, Juan-Mas, A, Almodovar-Gonzalez, R, Rodriguez-Garcia, S, Castellanos, R, Maiz-Alonso, O, Aguilera-Cros, C, Cabezas-Rodriguez, I, Cervantes, EC, Moreno, M, Arboleya, L, Montagut, C, Carreira, P, Ojeda-Garcia, C, Bonilla, G, Perez-Sandoval, T, Vela, P, Andreu, JL, Romero-Yuste, S, Urruticoechea-Arana, A, Salgado-Perez, E, Hidalgo, C, Narvaez, J, Raya, E, Moreno-Ramos, MJ, Morales-Garrido, P, Perez-Alba, L, Fernandez-Lopez, C, Villa, I, Alvarez-Rivas, N, Blanco-Madrigal, JM, Jimenez-Aberasturi, JR, Perez-Linaza, A, Del-val-del-amo, N, Fernandez, S, Garciavalle, A, Peralta-Gines, CA, Garcia-Aparicio, A, Exposito-perez, L, Mena-Vazquez, N, Lopez-Sanchez, R, Garcia-magallon, B, Gonzalez-Gay, MA, and Blanco, R
- Published
- 2019
18. Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients
- Author
-
Calderon-Goercke, M, Loricera, J, Prieto-Pena, D, Castaneda, S, Caceres, VA, Villa, I, Humbria, A, Moriano, C, Romero-Yuste, S, Narvaez, J, Gomez-Arango, C, Pampin, EP, Melero, R, Becerra-Fernandez, E, Revenga, M, Alvarez-Rivas, N, Galisteo, C, Sivera, F, Olive-Marques, A, del Buergo, MA, Marena-Rojas, L, Fernandez-Lopez, C, Navarro, F, Raya, E, Galindez-Agirregoikoa, E, Arca, B, Solans-Laque, R, Conesa, A, Hidalgo, C, Vazquez, C, Roman-Ivorra, JA, Lluch, P, Manrique, S, Vela, P, de Miguel, E, Torres-Martin, C, Nieto, JC, Ordas-Calvo, C, Salgado-Perez, E, Luna-Gomez, C, De Miera, FJTS, Fernandez-Llanio, N, Garcia, A, Larena, C, Varela-Garcia, M, Aurrecoechea, E, Ortiz-Sanjuan, F, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R
- Published
- 2019
19. Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone
- Author
-
Calderon-Goercke, M, Loricera, J, Prieto-Pena, D, Castaneda, S, Caceres, VA, Villa, I, Humbria, A, Moriano, C, Romero-Yuste, S, Narvaez, J, Gomez-Arango, C, Pampin, EP, Melero, R, Becerra-Fernandez, E, Revenga, M, Alvarez-Rivas, N, Galisteo, C, Sivera, F, Olive-Marques, A, del Buergo, MA, Marena-Rojas, L, Fernandez-Lopez, C, Navarro, F, Raya, E, Galindez-Agirregoikoa, E, Arca, B, Solans-Laque, R, Conesa, A, Hidalgo, C, Vazquez, C, Roman-Ivorra, JA, Lluch, P, Manrique, S, Vela, P, de Miguel, E, Torres-Martin, C, Nieto, JC, Ordas-Calvo, C, Salgado-Perez, E, Luna-Gomez, C, De Miera, FJTS, Fernandez-Llanio, N, Garcia, A, Aurrecoechea, E, Ortego, N, Ortiz-Sanjuan, F, Corteguera, M, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R
- Published
- 2019
20. Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms
- Author
-
Calderon-Goercke, M, Loricera, J, Prieto-Pena, D, Castaneda, S, Caceres, VA, Villa, I, Humbria, A, Moriano, C, Romero-Yuste, S, Narvaez, J, Gomez-Arango, C, Pampin, EP, Melero, R, Becerra-Fernandez, E, Revenga, M, Alvarez-Rivas, N, Galisteo, C, Sivera, F, Olive-Marques, A, del Buergo, MA, Marena-Rojas, L, Fernandez-Lopez, C, Navarro, F, Raya, E, Galindez-Agirregoikoa, E, Arca, B, Solans-Laque, R, Conesa, A, Hidalgo, C, Vazquez, C, Roman-Ivorra, JA, Lluch, P, Manrique, S, Vela, P, de Miguel, E, Torres-Martin, C, Nieto, JC, Ordas-Calvo, C, Salgado-Perez, E, Luna-Gomez, C, De Miera, FJTS, Fernandez-Llanio, N, Garcia, A, Larena, C, Varela-Garcia, M, Dos Santos, R, Ortego, N, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R
- Published
- 2019
21. Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous
- Author
-
Calderon-Goercke, M, Loricera, J, Prieto-Pena, D, Castaneda, S, Caceres, VA, Villa, I, Humbria, A, Moriano, C, Romero-Yuste, S, Narvaez, J, Gomez-Arango, C, Pampin, EP, Melero, R, Becerra-Fernandez, E, Revenga, M, Alvarez-Rivas, N, Galisteo, C, Sivera, F, Olive-Marques, A, del Buergo, MA, Marena-Rojas, L, Fernandez-Lopez, C, Navarro, F, Raya, E, Galindez-Agirregoikoa, E, Arca, B, Solans-Laque, R, Conesa, A, Hidalgo, C, Vazquez, C, Roman-Ivorra, JA, Lluch, P, Manrique, S, Vela, P, de Miguel, E, Torres-Martin, C, Nieto, JC, Ordas-Calvo, C, Salgado-Perez, E, Luna-Gomez, C, De Miera, FJTS, Fernandez-Llanio, N, Garcia, A, Larena, C, Varela-Garcia, M, Aurrecoechea, E, Ortiz-Sanjuan, F, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R
- Published
- 2019
22. AB0518 Efficacy of belimumab for primary sjÖgren syndrome: results of a systematic review of the literature
- Author
-
Park, H.S., primary, Alvarez-Rivas, N., additional, Diaz del Campo, P., additional, Fernandez-Castro, M., additional, Corominas, H., additional, Andreu, J.L., additional, and Navarro-Compán, V., additional
- Published
- 2018
- Full Text
- View/download PDF
23. Tumor-induced hypophosphatemic osteomalacia: description of 2 cases.
- Author
-
Alvarez-Rivas N, Vazquez-Rodriguez TR, and Garcia-Porrua C
- Subjects
- Female, Humans, Incidence, Magnetic Resonance Imaging, Middle Aged, Osteomalacia, Paraneoplastic Syndromes, Hypophosphatemia diagnostic imaging, Hypophosphatemia epidemiology, Hypophosphatemia therapy, Neoplasms, Connective Tissue diagnostic imaging, Neoplasms, Connective Tissue epidemiology, Neoplasms, Connective Tissue therapy
- Published
- 2019
- Full Text
- View/download PDF
24. Long-term survival of subcutaneous anti-tumor necrosis factor biological drugs administered between 2008 and 2012 in a cohort of rheumatoid arthritis patients.
- Author
-
Alvarez Rivas N, Vazquez Rodriguez TR, Miranda Filloy JA, Garcia-Porrua C, and Sanchez-Andrade Fernández A
- Subjects
- Adult, Aged, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor-alpha antagonists & inhibitors, Adalimumab therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Etanercept therapeutic use
- Abstract
Objective: To compare the survival of subcutaneous anti-tumor necrosis factor (TNF) drugs used between 2008 and 2012 prescribed in accordance with clinical practice., Material and Methods: Retrospective, observational study of the patients in our center diagnosed with rheumatoid arthritis (RA). We included patients who had received a subcutaneous anti-TNF agent for at least 6 months. The data were analyzed using the SPSS V17.0 statistical package., Results: Forty-nine RA patients started subcutaneous biological treatment with an anti-TNF agent (32 with etanercept and 17 with adalimumab). The mean age was 45.94 years (75.5% female). The mean disease duration prior to starting anti-TNF administration was 2.67 years. The mean age at the start of treatment was 51.84 years, and the average Disease Activity Score 28 was 4.93. The median survival of the anti-TNF treatment was 8.40 years; the survival of etanercept was the longer of the two. The main reason for discontinuation was secondary failure (90.9%)., Conclusions: In routine clinical practice, the survival of subcutaneous anti-TNF treatment was extensive and was independent of whether or not the patients received concomitant immunosuppressive therapy., (Copyright © 2017 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
25. Facticial panniculitis and Löfgren's syndrome: a case.
- Author
-
Diez Morrondo C, Palmou Fontana N, Lema Gontad JM, Alvarez Rivas N, Freire González M, García Silva J, Hermida Romero T, and Galdo F
- Subjects
- Adult, Erythema Nodosum etiology, Female, Humans, Panniculitis etiology, Sarcoidosis etiology, Syndrome, Cosmetic Techniques adverse effects, Erythema Nodosum diagnosis, Panniculitis diagnosis, Prostheses and Implants adverse effects, Sarcoidosis diagnosis, Silicones adverse effects
- Abstract
We herein report a patient who came to the hospital because of a polyarticular joint pain, fever and cutaneous lesions. She had silicone implants in her buttocks, a surgery performed 3 years before. We made a biopsy of the skin of the buttocks (facticial panniculitis due to silicone) and of the pretibial surface of the inferior extremities (erythema nodosum). A chest X- ray and a CT scan revealed bilateral hiliar lymphadenopathy, and a transbronquial biopsy showed granulomatous inflammation. She had a good response to rest and anti-inflammatory drugs, so the removal of the silicone implants has not been necessary yet., (Copyright © 2011 Elsevier España, S.L. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.